Log In
BCIQ
Print this Print this
 

CD19 x CD3 DART molecule (JNJ-64052781, MGD011)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD19 and CD3 developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD19 ; CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationB cell lymphoma
Indication DetailsTreat B cell malignancies
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$700.0M

$50.0M

$575.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/22/2014

$700.0M

$50.0M

$575.0M

Get a free BioCentury trial today